keyword
MENU ▼
Read by QxMD icon Read
search

HBsAg seroconversion

keyword
https://www.readbyqxmd.com/read/28078526/effectiveness-and-safety-of-entecavir-or-tenofovir-in-a-spanish-cohort-of-chronic-hepatitis-b-patients-validation-of-the-page-b-score-to-predict-hepatocellular-carcinoma
#1
Mar Riveiro-Barciela, David Tabernero, José L Calleja, Sabela Lens, María L Manzano, Francisco Gea Rodríguez, Javier Crespo, Belén Piqueras, Juan M Pascasio, Carmen Comas, Maria L Gutierrez, Alberto Aguirre, Emilio Suárez, Javier García-Samaniego, Miguel Rivero, Doroteo Acero, Miguel Fernandez-Bermejo, Diego Moreno, Pilar Sánchez-Pobre, Beatriz de Cuenca, J J Moreno-Palomares, Rafael Esteban, Maria Buti
BACKGROUND: Long-term antiviral therapy has resulted in viral suppression and biochemical response in chronic hepatitis B, although the risk of hepatocellular carcinoma has not been abolished. The Page-B score could be useful to estimate the probability of HCC. AIMS: To analyze the effectiveness and safety of entecavir or tenofovir for more than 4 years and the usefulness of Page-B score in the real-world setting. METHODS: Analysis of Caucasian chronic hepatitis B subjects treated with entecavir or tenofovir from the prospective, multicenter database CIBERHEP...
January 11, 2017: Digestive Diseases and Sciences
https://www.readbyqxmd.com/read/28052620/when-can-we-stop-nucleoside-analogues-in-patients-with-chronic-hepatitis-b
#2
REVIEW
Chern Hao Chong, Seng Gee Lim
Treatment with nucleoside analogue (NAs) is now the most common treatment for chronic hepatitis B (CHB) and is recommended by all guidelines. Stopping NAs is a controversial issue in these patients, unless the clinical endpoints of HBeAg seroconversion or HBsAg seroclearance are achieved. While HBeAg seroconversion can occur in a significant number of patients, HBsAg seroclearance rates are low. HBsAg seroclearance is increasingly accepted as the ideal end of treatment, representing a functional cure. Treatment withdrawal leads to relapse in 50% of patients who achieve HBeAg seroconversion and complete at least 12 months of consolidation therapy...
January 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28028369/effect-of-switching-from-treatment-with-nucleos-t-ide-analogs-to-pegylated-interferon-%C3%AE-2a-on-virological-and-serological-responses-in-chronic-hepatitis-b-patients
#3
Li-Ting He, Xiao-Guang Ye, Xiao-Yuan Zhou
AIM: To investigate the efficacy of switching to pegylated interferon-α-2a (PegIFNα-2a) treatment in nucleos(t)ide analog (NA)-treated chronic hepatitis B (CHB) responder patients. METHODS: A 48-wk prospective and retrospective treatment trial of NA-treated CHB patients who had received entecavir (ETV) for at least 48 wk and had serum hepatitis B virus (HBV)-DNA < 500 IU/mL, serum hepatitis B envelope antigen (HBeAg) < 100 S/CO, serum alanine aminotransferase, and aspartate aminotransferase levels < 2 × the upper limit of normal of 40 IU/L was performed...
December 14, 2016: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28005687/response-to-tenofovir-among-lamivudine-experienced-hepatitis-b-and-hiv-coinfected-adolescents
#4
Linda Aurpibul, Pagakrong Lumbiganon, Rawiwan Hansudewechakul, Suparat Kanjanavanit, Torsak Bunupuradah, Pope Kosalaraksa, Pawinee Taeprasert, Thanyawee Puthanakit
We determined hepatitis B virus (HBV) suppression rates among 18 lamivudine (3TC)-experienced HBV-HIV coinfected adolescents after treatment with tenofovir disoproxil fumurate (TDF). At TDF initiation, their median age was 17.6 years, and duration of 3TC-exposure was 7.3 years. Eleven patients (61%) achieved HBV DNA <60 IU/mL after 48 weeks on TDF and 3TC which was similar to adult studies, although HBsAg loss or HBeAb seroconversion did not occur.
December 21, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27936480/treatment-of-fulminant-acute-hepatitis-b-with-nucles-t-id-analogues-is-safe-and-does-not-lead-to-secondary-chronification-of-hepatitis-b
#5
C Jochum, F Maischack, O E Anastasiou, J Verheyen, J Timm, L Bechmann, G Gerken, A Canbay
Background: Acute hepatitis B virus (HBV) infection is still a major cause of acute liver failure (ALF), necessitating a high rate of emergency liver transplantation (LTx). Acute infection is followed by high viral replication rates leading to hepatocyte death and, ultimately, ALF. The objective of treating HBV-induced ALF thus is to eliminate, or significantly suppress, HBV replication and therefore reduce cell death and support regeneration. Objective: In this retrospective study, we want to evaluate the timing, the safety, and the long-term virological outcome of this approach...
December 2016: Zeitschrift Für Gastroenterologie
https://www.readbyqxmd.com/read/27917266/telbivudine-vs-tenofovir-in-hepatitis-b-e-antigen-negative-chronic-hepatitis-b-patients-optima-roadmap-study
#6
Zahari Krastev, Diana Petrova, Iskren Kotzev, Mustafa Kemal Celen, Meryl Mendelson, Richa Chandra, Priti Pandey, Kamal Hamed
AIM: To make efficacy and safety comparison of telbivudine-raodmap and tenofovir-roadmap in hepatitis B e antigen (HBeAg)-negative chronic hepatitis B (CHB) patients. METHODS: This was the first prospective, randomised, two-arm, open-label, non-inferiority study in HBeAg-negative CHB patients that compared telbivudine and tenofovir administered as per roadmap concept. Patients were treated up to 24 wk and, depending on virologic response, continued the same therapy or received add-on therapy up to 104 wk...
November 18, 2016: World Journal of Hepatology
https://www.readbyqxmd.com/read/27862721/efficacy-and-safety-of-tenofovir-disoproxil-fumarate-rescue-therapy-for-chronic-hepatitis-b-patients-who-failed-other-nucleos-t-ide-analogs
#7
Hiromitsu Kumada, Kazuhiko Koike, Kazuaki Suyama, Hiroshi Ito, Hiroshi Itoh, Wataru Sugiura
AIM: Acquisition of nucleos(t)ide analog (NA) inhibitor resistance is critical in successful chronic hepatitis B treatment. As the pattern of tenofovir disoproxil fumarate (TDF) resistance mutations differs from that of other antiviral drugs, we sought to clarify the salvaging potential of TDF in patients with hepatitis B virus (HBV) infection who are poor responders or resistant to other NAs. METHODS: A prospective, multicenter, single-arm, open-label study was carried out from December 2011 to October 2014...
November 15, 2016: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/27855500/treatment-of-hepatitis-b-virus-an-update
#8
Haley Ward, Lydia Tang, Bhawna Poonia, Shyam Kottilil
Chronic hepatitis B virus infection is a global health concern as it affects over 240 million people worldwide and an estimated 686,000 people die annually as a result of complications of the disease. With the development of newer antiviral drugs, viral suppression of HBV is achievable, however elimination of HBV from infected individuals (functional cure) remains an issue. Due to persistence of HBV DNA (cccDNA) in infected cells, chronically infected patients who discontinue therapy prior to HBsAg loss or seroconversion are likely to relapse...
December 2016: Future Microbiology
https://www.readbyqxmd.com/read/27793564/role-of-hbsag-decline-in-patients-with-chronic-hepatitis-b-hbeag-negative-and-e-genotype-treated-with-pegylated-interferon
#9
Lucio Boglione, Jessica Cusato, Giuseppe Cariti, Giovanni Di Perri, Antonio D'Avolio
Treatment options for patients with chronic hepatitis B (CHB) and hepatitis B e antigen (HBeAg)-negative are pegylated interferon alfa-2a (PEG-IFN) for 48 weeks or nucleos(t)ide analogues (NAs). The choice of patients with higher chance of sustained response (SR) to PEG-IFN can be made with pre-treatment and on-treatment factors; recent studies evidenced the role of early drop of serum hepatitis B surface antigen (HBsAg) as predictor of SR. The aim of this study was the evaluation of early decrease of HBsAg on the SR in HBeAg-negative patients with E genotype...
October 26, 2016: Antiviral Research
https://www.readbyqxmd.com/read/27793166/hbsag-and-hbeag-in-the-prediction-of-a-clinical-response-to-peginterferon-%C3%AE-2b-therapy-in-chinese-hbeag-positive-patients
#10
Song Yang, Huichun Xing, Yuming Wang, Jinlin Hou, Duande Luo, Qing Xie, Qin Ning, Hong Ren, Huiguo Ding, Jifang Sheng, Lai Wei, Shijun Chen, Xiaoling Fan, Wenxiang Huang, Chen Pan, Zhiliang Gao, Jiming Zhang, Boping Zhou, Guofeng Chen, Mobin Wan, Hong Tang, Guiqiang Wang, Yuxiu Yang, Dongping Xu, Peiling Dong, Qixin Wang, Jue Wang, Fernando A Bognar, Daozhen Xu, Jun Cheng
BACKGROUND: This study aimed to evaluate the predictive values of hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) levels in 171 Chinese patients with chronic hepatitis B who received a 48-week course of pegylated interferon alfa-2b therapy at 1.5 mcg/kg. METHODS: HBsAg, HBeAg, and hepatitis B virus (HBV) DNA levels were measured at baseline and weeks 12, 24, 48, and 72. Clinical responses were defined as a combined response (CR, HBeAg seroconversion [sustained response, SR] combined with HBV DNA level <2,000 IU/mL at week 72)...
October 28, 2016: Virology Journal
https://www.readbyqxmd.com/read/27769101/antiviral-response-is-not-sustained-after-cessation-of-lamivudine-treatment-in-chronic-hepatitis-b-patients-a-10-year-follow-up-study
#11
Seong Hee Kang, Keunhee Kang, Yeon Jong Eun, Young Sun Lee, Tae Suk Kim, Yang Jae Yoo, Sang Jun Suh, Eileen L Yoon, Young Kul Jung, Ji Hoon Kim, Yeon Seok Seo, Hyung Joon Yim, Kwan Soo Byun
Although the ideal end point for antiviral treatment in patients with chronic hepatitis B (CHB) is loss of HBsAg, the typical clinical end points are HBeAg seroconversion in HBeAg-positive patients and long-term DNA suppression in HBeAg-negative patients. We evaluated the long-term antiviral response after cessation of lamivudine treatment in CHB patients. A total of 157 patients who had discontinued lamivudine between 1997 and 2014 were enrolled (97 HBeAg-positive and 60 HBeAg-negative CHB patients). The long-term durability of the antiviral response (viralogical relapse; HBV DNA ≥10(4)  copies/ml) and the clinical course of these patients were analyzed retrospectively...
October 21, 2016: Journal of Medical Virology
https://www.readbyqxmd.com/read/27687670/-hbsag-seroconversion-after-entecavir-therapy-for-7-years-following-a-poor-response-to-interferon-%C3%AE-2b-monotherapy-in-a-hbeag-negative-patient-with-chronic-hepatitis-b
#12
Tao-Yuan Li, You-Peng Chen
We report a rare case of HBsAg seroconversion after 7 years of entecavir therapy in a 48-year-old HBeAg-negative CHB male patient with chronic hepatitis B (CHB). After a poor response to a 48-week interferon-α 2b therapy, the patient received long-term entecavir therapy. Serum ALT levels became normal and HBV DNA viral load was undetectable at the 10th week after commencement of entecavir treatment, and seroconversion of HBsAg was detected after 7 years of entecavir therapy.
August 20, 2016: Nan Fang Yi Ke da Xue Xue Bao, Journal of Southern Medical University
https://www.readbyqxmd.com/read/27647214/prevalence-of-hepatitis-b-surface-antigen-hbsag-in-a-blood-donor-population-born-prior-to-and-after-implementation-of-universal-hbv-vaccination-in-shenzhen-china
#13
Zhen Wang, Jinfeng Zeng, Tingting Li, Xin Zheng, Xiaoxuan Xu, Xianlin Ye, Liang Lu, Weigang Zhu, Baocheng Yang, Jean-Pierre Allain, Chengyao Li
BACKGROUND: Neonatal hepatitis B vaccination program at birth has been implemented nationwide since 1992 in China. However, current HBV prevalence status in blood donors has not been entirely examined, which may impact HBV safety in blood donations as the vaccinees over 18 years old progressively become the majority population of blood donors. METHODS: In this study, 569,145 blood donors were screened for HBsAg by rapid tests and enzyme immunoassays, among them 475,538 blood samples with negative HBsAg were further screened for HBV DNA by nucleic acid testing between 2005 and 2014 at Shenzhen blood center...
2016: BMC Infectious Diseases
https://www.readbyqxmd.com/read/27545497/tenofovir-disoproxil-fumarate-tdf-vs-emtricitabine-ftc-tdf-in-lamivudine-resistant-hepatitis-b-a-5-year-randomised-study
#14
Scott Fung, Peter Kwan, Milotka Fabri, Andrzej Horban, Mijomir Pelemis, Hie-Won Hann, Selim Gurel, Florin A Caruntu, John F Flaherty, Benedetta Massetto, Kyungpil Kim, Kathryn M Kitrinos, G Mani Subramanian, John G McHutchison, Leland J Yee, Magdy Elkhashab, Thomas Berg, Ioan Sporea, Cihan Yurdaydin, Petr Husa, Maciej S Jablkowski, Edward Gane
BACKGROUND & AIMS: Long-term treatment with tenofovir disoproxil fumarate (TDF) alone, or in combination with emtricitabine (FTC) is associated with sustained viral suppression in patients with lamivudine resistant (LAM-R) chronic hepatitis B (CHB). METHODS: LAM-R CHB patients were randomised 1:1 to receive TDF 300mg or FTC 200mg and TDF 300mg once daily in a prospective, double blind, study. The proportion of patients with plasma hepatitis B virus (HBV) DNA<69IU/ml (<400copies/ml) at week 96 (primary efficacy endpoint) was reported previously...
January 2017: Journal of Hepatology
https://www.readbyqxmd.com/read/27534671/deep-sequencing-shows-that-hbv-basal-core-promoter-and-precore-variants-reduce-the-likelihood-of-hbsag-loss-following-tenofovir-disoproxil-fumarate-therapy-in-hbeag-positive-chronic-hepatitis-b
#15
Julianne Bayliss, Lilly Yuen, Gillian Rosenberg, Darren Wong, Margaret Littlejohn, Kathleen Jackson, Anuj Gaggar, Kathryn M Kitrinos, G Mani Subramanian, Patrick Marcellin, Maria Buti, Harry L A Janssen, Ed Gane, Vitina Sozzi, Danni Colledge, Rachel Hammond, Rosalind Edwards, Stephen Locarnini, Alexander Thompson, Peter A Revill
OBJECTIVE: Hepatitis B e antigen (HBeAg) seroconversion and hepatitis B surface antigen (HBsAg) loss are important clinical outcomes for patients with chronic hepatitis B (CHB) treated with antiviral therapy. To date, there have been few studies that have evaluated viral sequence markers predicting serological response to nucleos(t)ide analogue (NA) treatment. DESIGN: We used next-generation sequencing (NGS) and quantitative HBV serology (HBeAg and HBsAg) to identify viral sequence markers associated with serological response to long-term tenofovir disoproxil fumarate therapy among HBeAg-positive patients...
August 17, 2016: Gut
https://www.readbyqxmd.com/read/27512071/in-vitro-studies-show-that-sequence-variability-contributes-to-marked-variation-in-hepatitis-b-virus-replication-protein-expression-and-function-observed-across-genotypes
#16
Vitina Sozzi, Renae Walsh, Margaret Littlejohn, Danni Colledge, Kathy Jackson, Nadia Warner, Lilly Yuen, Stephen A Locarnini, Peter A Revill
: The hepatitis B virus (HBV) exists as 9 major genotypes (A to I), one minor strain (designated J) and multiple subtypes. Marked differences in HBV natural history, disease progression and treatment response are exhibited by many of these genotypes and subtypes. For example, HBV genotype C is associated with later hepatitis B e antigen (HBeAg) seroconversion and high rates of liver cancer compared to other HBV genotypes, whereas genotype A2 is rarely associated with HBeAg-negative disease or liver cancer...
November 15, 2016: Journal of Virology
https://www.readbyqxmd.com/read/27495085/consort-effects-of-adding-adefovirdipivoxil-to-peginterferon-alfa-2a-at-different-time-points-on-hbeag-positivepatients-a-prospective-randomized-study
#17
Ka Zhang, Hong Cao, Jiayi Liang, Xin Shu, Haixia Sun, Gang Li, Qihuan Xu
BACKGROUND: The aims of this study were to compare the efficacy and safety of the addition of adefovir dipivoxil (ADV) (started at different time points) to pegylated interferon alpha-2a (PEG-INF-α2a) and PEG-INF-α2a monotherapy. This prospective, randomized study sought to evaluate the safety and efficacy of the combination of PEG-INF-α2a and ADV at different time points.120 patients were randomized into groups that received PEG-INF-α2a as monotherapy (group A) or in combination with ADV started at week 0 (group B), 12 (group C), or 24 (group D)...
August 2016: Medicine (Baltimore)
https://www.readbyqxmd.com/read/27493674/chitosan-and-sodium-alginate-combinations-are-alternative-efficient-and-safe-natural-adjuvant-systems-for-hepatitis-b-vaccine-in-mouse-model
#18
Nourhan H AbdelAllah, Nourtan F Abdeltawab, Abeer A Boseila, Magdy A Amin
Hepatitis B viral (HBV) infections represent major public health problem and are an occupational hazard for healthcare workers. Current alum-adjuvanted HBV vaccine is the most effective measure to prevent HBV infection. However, the vaccine has some limitations including poor response in some vaccinee and being a frost-sensitive suspension. The goal of our study was to use an alternative natural adjuvant system strongly immunogenic allowing for a reduction in dose and cost. We tested HBV surface antigen (HBsAg) adjuvanted with chitosan (Ch) and sodium alginate (S), both natural adjuvants, either alone or combined with alum in mouse model...
2016: Evidence-based Complementary and Alternative Medicine: ECAM
https://www.readbyqxmd.com/read/27470620/-efficacy-of-104-week-sequential-therapy-with-telbivudine-or-entecavir-in-hbeag-positive-chronic-hepatitis-b-patients-with-suboptimal-responses-to-24-week-therapy-with-pegylated-interferon-%C3%AE-2a
#19
RANDOMIZED CONTROLLED TRIAL
X D Luo, X P Chen, R Chen, X F Chen, J Huang
OBJECTIVE: To investigate the efficacy and safety of 104-week sequential therapy with telbivudine or entecavir in HBeAg-positive chronic hepatitis B (CHB) patients with suboptimal responses to 24-week pegylated interferon-α-2a (PEG-IFN-α-2a) therapy. METHODS: A total of 130 HBeAg-positive CHB patients with HBV DNA≥5.0 lg IU/ml and a reduction in HBsAg quantitation < 1 lg IU/ml compared with baseline who received PEG-IFN-α-2a therapy for 24 weeks were enrolled and randomly divided into telbivudine group and entecavir group, and 5 of them were lost...
April 2016: Zhonghua Gan Zang Bing za Zhi, Zhonghua Ganzangbing Zazhi, Chinese Journal of Hepatology
https://www.readbyqxmd.com/read/27447092/hbv-cure-why-how-when
#20
REVIEW
Massimo Levrero, Barbara Testoni, Fabien Zoulim
Current HBV treatments control replication and liver disease progression in the vast majority of treated patients. However, HBV patients often require lifelong therapies due to the persistence of transcriptionally active viral cccDNA mini-chromosome in the nucleus, which is not directly targeted by current antiviral therapies. A true complete cure of HBV would require clearance of intranuclear cccDNA from all infected hepatocytes. An intermediate but still relevant step forward that would allow treatment cessation would be reaching a functional cure, equivalent to resolved acute infection, with a durable HBsAg loss±anti-HBs seroconversion, undetectable serum DNA and persistence of cccDNA in a transcriptionally inactive status...
June 2016: Current Opinion in Virology
keyword
keyword
31626
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"